Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SUPN stock price vs H: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at H's multiple
Needs H P/S.
Implied fair value · at SUPN's multiple
Needs SUPN P/S.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SUPN FY 2025 (ended Dec 31, 2025) · H FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Bear
$11.78
Base
$13.86
Bull
$15.94
Hyatt Hotels Corp · implied price per share
Bear
$12.54
Base
$14.75
Bull
$16.96
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.02x
1.28x
Net debt / EBITDA
Leverage against operating earnings
-6.69x
4.04x
Cash and equivalents
Liquid reserves on the balance sheet
$496.66M
$813.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
SUPN vs JAZZ
INCYTE CORP
SUPN vs INCY
ANI PHARMACEUTICALS INC
SUPN vs ANIP
Vanda Pharmaceuticals Inc.
SUPN vs VNDA
Harmony Biosciences Holdings, Inc.
SUPN vs HRMY
MARRIOTT INTERNATIONAL INC /MD/
SUPN vs MAR
Hilton Worldwide Holdings Inc.
SUPN vs HLT
CHOICE HOTELS INTERNATIONAL INC /DE
SUPN vs CHH
WYNDHAM HOTELS & RESORTS, INC.
SUPN vs WH
HOST HOTELS & RESORTS, INC.
SUPN vs HST
INTERCONTINENTAL HOTELS GROUP PLC /NEW/
SUPN vs IHG
$23.23M
$4.28B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SUPN can turn its high gross margin and above-H revenue growth into sustained operating and net profitability, then holding or buying on weakness may make sense; otherwise, the current valuation looks difficult to justify because SUPN trades richer than H on P/S and EV/EBITDA while still posting negative operating margin and a weak F-Score.
SUPN trades at 3.9x P/S versus H at 2.6x, while the model-implied price is $32.12 versus the current $48.05, implying 33.2% downside. The valuation gap is not supported by a clear profitability advantage, since SUPN is loss-making and H also has negative net income but higher EBITDA margin and stronger leverage characteristics.
Supporting Metrics
